Novo Nordisk Fights Back With DKK 10.25 Billion Buyback as Danish Watchdog Flags Fourth Breach
Published on 10/09/2026 at 10:20 | Editorial boerse-global.de
Novo Nordisk is leaning on a combination of cost discipline, pipeline acquisitions and large-scale share repurchases to counter persistent valuation pressure, even as regulatory setbacks mount on its home turf.
The Danish drugmaker's stock changed hands at EUR 33.83 in today's session, a modest 0.4% decline that extends its year-to-date loss to 23%. Tuesday's close had been EUR 33.97, with the same 23% decline logged since the start of the year.
Management is pursuing a tighter cost base alongside acquisitions aimed at strengthening the future product portfolio, with the goal of shoring up its long-term position in metabolic diseases while gaining organizational efficiency. The share price reaction reflects how much tougher investor demands on growth have become — and Novo Nordisk is answering with changes at the operational level.
13,000 Jobs Cut as Growth Strategy Gets an Overhaul
At its capital markets day on September 21, the company laid out a long-term growth strategy that includes cutting roughly 13,000 positions across the group. Media reports noted that pre-market US trading saw the stock drop 5.00% that day.
Beyond internal streamlining, the company is bringing in outside assets to broaden its therapeutic reach.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Hengrui Deal and Wegovy Liver Data
An exclusive licensing agreement with Hengrui Pharma, signed September 29, covers the drug candidate HRS-1596 — an oral dual GLP-1/GIP agonist in Phase 1 clinical testing. Novo Nordisk secured development, manufacturing and commercialization rights outside mainland China, Hong Kong, Macao and Taiwan for a potential total value of up to USD 2.6 billion, including a USD 300 million upfront payment.
Alongside new candidates, the company is reviewing the potential of existing treatments in additional indications.
On October 1, Novo Nordisk published an exploratory post-hoc analysis from a subgroup of the STEP-UP trial involving 55 participants. After 72 weeks of treatment with Wegovy, previously elevated liver fat levels normalized in 88.5% of subjects.
Buyback Total Reaches DKK 10.25 Billion
Capital allocation is another lever against the market backdrop. Novo Nordisk said Monday that repurchases under its DKK 15 billion buyback program had reached DKK 10,247,270,869 since February 4, 2026. Its holding of own B shares stood at 1.1% of share capital.
Regulatory processes have hit delays elsewhere. The US Food and Drug Administration's review of the marketing application for Denecimig in hemophilia A remains ongoing because of remediation work at production sites. Since the agency found no deficiencies in clinical efficacy or safety data, Novo Nordisk sees no impact on its 2026 financial guidance and is targeting a US launch in the first half of 2027.
Danish Regulator Cites Fourth Violation of 2026
At home, the Danish medicines authority has accused Novo Nordisk of repeated breaches of the law. According to media reports, the pharmaceutical company has violated statutory provisions four times in 2026. Three of those cases involved unauthorized advertising for weight-loss drugs on LinkedIn that was directed straight at consumers.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
Danish rules strictly prohibit direct-to-public advertising of prescription medicines, and the finding adds to a string of regulatory rebukes in the company's home market.
The Danish pharmaceutical industry's ethics committee had already fined the company on September 28. Over a joint program with service provider Falck to support Wegovy patients, the panel demanded a penalty of DKK 45,000 plus VAT and ordered the program be discontinued in its then-current form. Media reports said Novo Nordisk subsequently ended the Falck collaboration, while stressing it disagreed with the ethics council's decision.
Analysts Trim Targets, Keep Divergent Ratings
The regulatory friction lands in an already demanding market environment. On Wednesday, Danske Bank lowered its price target for Novo Nordisk from DKK 365 to DKK 345 while keeping its "Buy" rating. Deutsche Bank, by contrast, maintained its "Sell" rating and cut its target from DKK 245 to DKK 225 after data from the EASD diabetes conference was judged subdued.
While the GLP-1 business keeps expanding globally, the Copenhagen reprimands make plain the tight limits supervisors are placing on how the sought-after medicines may be marketed.
Ad
Novo Nordisk Stock: New Analysis - 9 October
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
